Nonalcoholic Fatty Liver Disease

TABLE 1

Anthropometric, clinical, and laboratory data in NAFLD patients, type 2 diabetic patients, and control subjects

NAFLD patients Type 2 diabetic patients Control subjects
n 30 10 10
Sex (M/F) 24/6 8/2 8/2
Age (years) 41 ± 11 (24–64)* 56 ± 8 (45–67) 48 ± 14 (26–60)
Weight (kg) 81 ± 10 (65–96) 84 ± 10 (66–105) 73 ± 11 (57–94)
BMI (kg/m2) 27 ± 2 (23–29) 29 ± 4 (24–37) 24 ± 2 (21–28)
Waist circumference (cm) 100 ± 8 (87–115) 98 ± 8 (77–109) 85 ± 12 (73–100)
Hip circumference (cm) 106 ± 6 (94–117) 109 ± 10 (100–135) 101 ± 6 (90–109)
Waist-to-hip ratio 0.94 ± 0.06 (0.80-1.08) 0.92 ± 0.09 (0.71–1.04) 0.84 ± 0.10 (0.71–0.95)
Fasting glucose (mmol/l) 5.2 ± 0.5 (4.4–6.0)* 6.3 ± 0.4 (5.7–7.1) 5.0 ± 0.4 (4.4–5.7)
120-min OGTT glucose (mmol/l) 5.7 ± 0.9 (4.1–7.2) Not determined 5.9 ± 0.8 (4.7–7.2)
Total cholesterol (mmol/l) 5.5 ± 1.1 (3.9–9.1) 5.0 ± 0.8 (4.0–6.5) 4.9 ± 0.9 (3.4–5.9)
HDL cholesterol (mmol/l) 1.1 ± 0.3 (0.7–2.1) 1.0 ± 0.2 (0.7–1.4) 1.5 ± 0.3 (1.0–2.1)
Triglycerides (mmol/l) 2.3 ± 1.0 (0.9–4.9) 2.3 ± 1.2 (0.7–4.3) 1.1 ± 0.4 (0.6–1.6)
Uric acid (μmol/l) 349 ± 64 (208–476) 358 ± 73 (227–479) 235 ± 59 (156–329)
Fasting insulin (pmol/l) 124 ± 58 (43–265) 143 ± 59 (86–258) 44 ± 20 (14–79)
Fasting C-peptide (pmol/ml) 1,080 ± 236 (719–1,548) 900 ± 298 (525–1,548) 677 ± 200 (498–1,161)
AST (units/l) 42 ± 16 (25–98)* 19 ± 7 (12–29) 16 ± 5 (10–22)
ALT (units/l) 90 ± 40 (44–203)* 29 ± 10 (15–44) 22 ± 7 (12–33)
  • Data are means ± SD (range). Normal AST and ALT values <40 units/l.

  • *

    * P < 0.005 vs. patients with type 2 diabetes;

  • P < 0.005 vs. control subjects.

This Article

  1. Diabetes vol. 50 no. 8 1844-1850